

STN- Registry / CAPLUS

10/506,554

05/10/2006

100.0% PROCESSED 301108 ITERATIONS
SEARCH TIME: 00.00.04

0 ANSWERS

L3 0 SEA SSS FUL L1


=> s 12 full
FULL SEARCH INITIATED 12:42:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 301108 TO ITERATE

100.0% PROCESSED 301108 ITERATIONS
SEARCH TIME: 00.00.06

93 ANSWERS

L4 93 SEA SSS FUL L2

=>
Uploading C:\Program Files\Stnexp\Queries\10506554\10, r = 1 (5MR) 2.str



r=1, 5-membered ring

chain nodes :
10 11 12 15 16 18 24 33 34 35 36
ring nodes :
1 2 3 4 5 6 7 8 9 19 20 21 22 23 26 27 28 29
chain bonds :
1-36 2-35 3-34 4-33 7-18 8-10 9-15 10-11 10-12 12-16 21-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 19-21 19-20 20-23 21-22 22-23
22-26 23-29 26-27 27-28 28-29
exact/norm bonds :
1-36 2-35 3-34 4-33 5-7 6-9 7-8 7-18 8-9 10-11 10-12 19-21 19-20 20-23
21-22 21-24 22-23 22-26 23-29 26-27 27-28 28-29
exact bonds :
8-10 9-15 12-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:O,N

G2:H,CH3

G3:H,X,CH3


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 15:CLASS 16:CLASS 18:CLASS 19:Atom 20:Atom 21:Atom
22:Atom 23:Atom 24:CLASS 25:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 33:CLASS
34:CLASS 35:CLASS 36:CLASS

L5 STRUCTURE UPLOADED

=> d

L5 HAS NO ANSWERS

L5 STR



G1 O, N

G2 H, Me

G3 H, X, Me

Structure attributes must be viewed using STN Express query preparation.

=> s l5 full

FULL SEARCH INITIATED 12:45:18 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 301108 TO ITERATE


100.0% PROCESSED 301108 ITERATIONS
SEARCH TIME: 00.00.04

99 ANSWERS

L6 99 SEA SSS FUL L5

=>

Uploading C:\Program Files\Stnexp\Queries\10506554\10, r = 2.str



chain nodes :

10 11 12 15 16 18 23 34 35 36 37

ring nodes :

1 2 3 4 5 6 7 8 9 19 20 21 22 24 25 26 27 28 29

chain bonds :

1-37 2-36 3-35 4-34 7-18 8-10 9-15 10-11 10-12 12-16 20-23

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 19-22 19-28 20-21 20-29 21-22
21-24 22-27 24-25 25-26 26-27 28-29

exact/norm bonds :

1-37 2-36 3-35 4-34 5-7 6-9 7-8 7-18 8-9 10-11 10-12 19-22 19-28 20-23
20-21 20-29 21-22 21-24 22-27 24-25 25-26 26-27 28-29

exact bonds :

8-10 9-15 12-16

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:O,N

G2:H,CH3

G3:H,X,CH3

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 15:CLASS 16:CLASS 18:CLASS 19:Atom 20:Atom 21:Atom
22:Atom 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:CLASS
34:CLASS 35:CLASS 36:CLASS 37:CLASS

L7 STRUCTURE UPLOADED

=> d

L7 HAS NO ANSWERS

L7 STR



G1 O,N
 G2 H,Me
 G3 H,X,Me

r=2 6 membered ring

Structure attributes must be viewed using STN Express query preparation.

=> s 17 full
 FULL SEARCH INITIATED 12:46:43 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 301108 TO ITERATE

100.0% PROCESSED 301108 ITERATIONS
 SEARCH TIME: 00.00.04

L8 0 SEA SSS FUL L7

=> fil caplus
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
670.84	671.05

FILE 'CAPLUS' ENTERED AT 12:46:52 ON 10 MAY 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 May 2006 VOL 144 ISS 20
 FILE LAST UPDATED: 9 May 2006 (20060509/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.

They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 16

L9 3 L6

=> d ibib abs hitstr 1-3

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:216668 CAPLUS

DOCUMENT NUMBER: 142:297984

TITLE:

Preparation of indole-2-carboxamide derivatives as glycogen phosphorylase inhibitors

INVENTOR(S): Bennett, Stuart Norman Lile; Simpson, Iain

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020985	A1	20050310	WO 2004-GB3620	20040825
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HL, HR, NE, SN, TD, TG				


PRIORITY APPLN. INFO.:			
	GB 2003-20242	A	20030829
	GB 2004-1800	A	20040128

OTHER SOURCE(S): MARPAT 142:297984

GI




L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847658-36-0 CAPLUS
 CN Carbamic acid, [(1R,2R)-2-[[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl](2-hydroxyethyl)-, (4-nitrophenyl)methyl ester (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



RN 847658-37-1 CAPLUS
 CN Carbamic acid, [(1R,2R)-2-[[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl](2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl)-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


AB Title compds. represented by the formula I [wherein A = phenylene or heteroarylene; n = 0-2; m = 0-2; R1 = independently halo, NO2, CN, carbamoyl, etc.; R2R3 = (un)substituted heterocyclic ring; R4 = independently halo, OH, carboxy, etc.; with a proviso: and pharmaceutically acceptable salts or prodrugs thereof] were prepared as glycogen phosphorylase inhibitors (no data). For example, II was given

in a multi-step synthesis starting from 5-chloroindole-2-carboxylic acid. I and their pharmaceutical compns. are useful as glycogen phosphorylase inhibitors for the treatment of disease states associated with increased glycogen phosphorylase activity (no data).

IT 597555-50-5P 846542-86-7P 847658-36-0P
 847658-37-1P 847658-38-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

RN 597555-50-5 CAPLUS
 CN Carbamic acid, [(1R,2R)-2-[[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846542-86-7 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847658-38-2 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl]-5-chloro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:182625 CAPLUS

DOCUMENT NUMBER: 142:261398

TITLE: Preparation of indole-2-carboxamide derivatives as glycogen phosphorylase inhibitors
 INVENTOR(S): Bennett, Stuart Norman Lile; Simpson, Iain; Whittamore, Paul Robert Owen

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 74 pp.

CODEN: FIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019172	A1	20050303	WO 2004-GB3552	20040818
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			GB 2003-19690	A 20030822

OTHER SOURCE(S): MARPAT 142:261398

GI

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. represented by the formula I [wherein A = phenylene or heteroarylene; n = 0-2; m = 0-2; R1 = independently halo, NO2, CN, carbamoyl, etc.; R2, R3 = independently (halo)alkyl, CF3, hydroxyalkyl, etc.; R4 = independently halo, OH, carboxy, etc.] and pharmaceutically acceptable salts or prodrugs thereof were prepared as glycogen phosphorylase inhibitors. For example, II*HCl was given in a multi-step synthesis starting from 5-chloroindole-2-carboxylic acid. II showed 173 µM thermodyn. solubility and plasma protein binding activity

with Ki value of 0.5 µM. Thus, I and their pharmaceutical compds. are useful as glycogen phosphorylase inhibitors for the treatment of disease states associated with increased glycogen phosphorylase activity.

IT 846542-52-7P 846542-53-8P 846542-54-9P
 846542-55-0P 846542-56-1P 846542-57-2P
 846542-58-3P 846542-59-4P 846542-60-7P
 846542-61-8P 846542-62-9P 846542-63-0P
 846542-64-1P 846542-65-2P 846542-67-4P
 846542-68-5P 846542-69-6P 846542-70-9P
 846542-71-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indole-2-carboxamide derivs. as glycogen phosphorylase inhibitors)

RN 846542-52-7 CAPLUS

CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-1-[(2S)-2,3-dihydroxy-1-oxopropyl]methylamino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 846542-53-8 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-[(2S)-2-amino-3-hydroxy-1-oxopropyl]methylamino]-2,3-dihydro-1H-inden-2-yl]-5-chloro-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 846542-54-9 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-[(2S)-2-(acetylamino)-3-hydroxy-1-oxopropyl]methylamino]-2,3-dihydro-1H-inden-2-yl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-55-0 CAPLUS

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Pentanediamide, N1-[(1R,2R)-2-[(5-fluoro-1H-indol-2-yl)carbonylamino]-2,3-dihydro-1H-inden-1-yl]-2-hydroxy-N1-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846542-56-1 CAPLUS

CN Pentanediamide, N1-[(1R,2R)-2-[(5-fluoro-1H-indol-2-yl)carbonylamino]-2,3-dihydro-1H-inden-1-yl]-2-hydroxy-N1-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-57-2 CAPLUS

CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxy-3-methoxy-1-oxopropyl]methylamino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 846542-58-3 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxy-3-methoxy-1-oxopropyl]methylamino]-1H-inden-2-yl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-59-4 CAPLUS
 CN Butanediamide,
 N1-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-2-hydroxy-N1-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 846542-63-0 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxy-1-oxobutyl]methylamino]-1H-inden-2-yl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846542-64-1 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxy-1-oxobutyl]methylamino]-1H-inden-2-yl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-65-2 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxy-1-oxobutyl]methylamino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 846542-60-7 CAPLUS
 CN Butanediamide,
 N1-[(1R,2R)-2-[(5-fluoro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-2-hydroxy-N1-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846542-61-8 CAPLUS
 CN Butanediamide,
 N1-[(1R,2R)-2,3-dihydro-2-[(1H-indol-2-ylcarbonyl)amino]-1H-inden-1-yl]-2-hydroxy-N1-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846542-62-9 CAPLUS
 CN Butanediamide, N1-[(1R,2R)-2,3-dihydro-2-[(5-methyl-1H-indol-2-yl)carbonyl]amino]-1H-inden-1-yl]-2-hydroxy-N1-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 846542-67-4 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxy-1-oxobutyl]methylamino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846542-68-5 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-[(2S)-2,3-dihydroxy-1-oxopropyl]methylamino]-2,3-dihydro-1H-inden-2-yl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846542-69-6 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxyethyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 846542-70-9 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2-hydroxyethyl)[(2S)-2-hydroxy-1-oxobutyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-71-0 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonylmethylamino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 597555-50-5P 846542-72-1P 846542-73-2P
 846542-74-3P 846542-75-4P 846542-76-5P
 846542-77-6P 846542-78-7P 846542-79-8P


L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 846542-74-3 CAPLUS
 CN Carbamic acid, [(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonylamino]-2,3-dihydro-1H-inden-1-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846542-75-4 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-(methylamino)-1H-inden-2-yl]-5-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 846542-76-5 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-(methylamino)-1H-inden-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)


L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

846542-80-1P 846542-81-2P 846542-82-3P
 846542-83-4P 846542-84-5P 846542-85-6P
 846542-86-7P 846542-87-8P 846542-88-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of indole-2-carboxamide derivs. as glycogen phosphorylase inhibitors)

RN 597555-50-5 CAPLUS

CN Carbamic acid, [(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonylamino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846542-72-1 CAPLUS

CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonylmethylamino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846542-73-2 CAPLUS


CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-(methylamino)-1H-inden-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Absolute stereochemistry.



● HCl

RN 846542-77-6 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-(methylamino)-1H-inden-2-yl]-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 846542-78-7 CAPLUS
 CN Carbamic acid, [(1R,2R)-2-[(5-fluoro-1H-indol-2-yl)carbonylamino]-2,3-dihydro-1H-inden-1-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-79-8 CAPLUS

CN Carbamic acid, [(1R,2R)-2,3-dihydro-2-[(1H-indol-2-ylcarbonyl)amino]-1H-


L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN inden-1-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-80-1 CAPLUS
CN Carbanic acid, [(1R,2R)-2,3-dihydro-2-[[5-methyl-1H-indol-2-yl]carbonyl]amino]-1H-inden-1-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846542-81-2 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[methyl[(2S)-tetrahydro-5-oxo-2-furanyl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846542-82-3 CAPLUS


L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 846542-85-6 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[[[(2S)-2-hydroxy-1-oxobutyl][2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846542-86-7 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846542-87-8 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl]-5-chloro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 597554-85-3
CMF C18 H16 Cl N3 O

Absolute stereochemistry.


L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-[methyl[(2S)-tetrahydro-5-oxo-2-furanyl]carbonyl]amino]-1H-inden-2-yl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-83-4 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[methyl[(2S)-oxiranylcabonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-84-5 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-[methyl[(2S)-oxiranylcabonyl]amino]-1H-inden-2-yl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 846542-88-9 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-1-[[[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]methylamino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STM
 ACCESSION NUMBER: 2003:719447 CAPLUS
 DOCUMENT NUMBER: 139:245895
 TITLE: Preparation of indolamide derivatives that possess glycogen phosphorylase inhibitory activity
 INVENTOR(S): Whittamore, Paul Robert Owen; Bennett, Stuart Norman
 Lile; Simpson, Iain
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 90 pp.
 CODEN: PIXXD2
 LANGUAGE: English
 DOCUMENT TYPE: Patent
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

Instant App.


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074484	A1	20030912	WO 2003-GB883	20030304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2477717	AA	20030912	CA 2003-2477717	20030304
AU 2003216988	A1	20030916	AU 2003-216988	20030304
BR 2003008144	A	20041207	BR 2003-8144	20030304
EP 1483240	A1	20041208	EP 2003-712310	20030304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005107362	A1	20050519	US 2003-506554	20030304
CN 1639120	A	20050716	CN 2003-805308	20030304
JP 2005524667	T2	20050811	JP 2003-772954	20030304
ZA 2004006681	A	20050922	ZA 2004-6681	20040823
NO 2004004032	A	20041005	NO 2004-4032	20040924
PRIORITY APPLN. INFO.:			GB 2002-5176	A 20020306
			WO 2003-GB883	W 20030304

OTHER SOURCE(S): MARPAT 139:245895
 GI




L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)
 (carboxymethyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloroindole-2-carboxamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate) prepn. of indolamide derivs. that possess glycogen phosphorylase inhibitory activity
 RN 597554-89-7 CAPLUS
 CN Carbamic acid, [2-[[[(1R,2R)-2-[[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597554-91-1 CAPLUS
 CN Carbamic acid, [(1S)-1-acetyl-3-[[[(1R,2R)-2-[[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-23-2 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[1-[(cyanomethyl)amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)
 AB Heterocyclic amides of formula (I): 5-chloro-2-[(N-(1-hydroxyindan-2-yl)carbonyl)amino]indole; A is phenylene or heteroarylene; m is 0, 1 or 2; n is 0, 1 or 2; R1 = for example halo, nitro, cyano, hydroxy, carboxy; r is 1 or 2; Y is -NR2R3 or -OR3; R2 and R3 = for example H, hydroxy, aryl, heterocyclyl and C1-4 alkyl((un)substituted by 1 or 2 R8 groups); R4 = for example H, halo, nitro, cyano, hydroxy, C1-4 alkyl, and C1-4 alkanoyl; R8 = for example hydroxy, -C(=O)N(R9)(R10), -NHC(O)R9, (R9)(R10)N- and -C(=O)R9; R9 and R10 = for example H, hydroxy, C1-4 alkyl((un)substituted by 1 or 2 R13); R13 = hydroxy, halo, trihalomethyl and C1-4 alkoxy) or a pharmaceutically acceptable salt or prodrug thereof are claimed. They possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity, e.g. type 2 diabetes, insulin resistance, syndrome X, hyperinsulinemia, hyperglucagonemia, cardiac ischemia, obesity. Inhibitory activity (IC50) of 1 in the direction of glycogen synthesis and on glycogen degradation were measure and are generally

100 μM to 1 nM; 7.4 μM for 5-chloro-N-[(1R,2R)-1-[[[(2-hydroxyethyl)(phenylmethyl)amino]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide in the latter assay. Processes for the manufacture of said heterocyclic amide derivs. and pharmaceutical compns. containing them are described. Thirty-seven example preps. and/or characterization data for 1 and 11 for intermediates are included. For example, to prepare 5-chloro-2-[(N-(trans-1-hydroxyindan-2-yl)carbonyl)amino]indole, 5-chloro-1H-indole-2-carboxylic acid (0.67 mmol) was dissolved in CH2Cl2 (10 mL) containing DIPEA (1.19 mmol) and trans-2-aminoindan-1-ol (0.67 mmol) and HATU (0.67 mmol); the reaction mixture was stirred at room temperature for approx. 18 h; workup gave 100 % of the desired compound. To prepare trans-2-aminoindan-1-ol, isoamyl nitrite (108 mmol) was added to a solution of indan-1,2-dione (90 mmol) in MeOH (380 mL) at 45 °C followed by concentrated HCl (12 mL) dropwise over 5 min; the reaction mixture was stirred for 3 h at room temperature; workup gave indan-1,2-dione-2-oxime (43%), which (39 mmol) in EtOH (470 mL) and 4M HCl/dioxane (36 mL) was hydrogenated at room temperature and 40 psi; workup gave 86 % of the trans-2-aminoindan-1-ol. IT 597554-89-7P, 5-Chloro-N-[(1R,2R)-1-[(tert-butoxycarbonyl)amino]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597554-91-1P, N-[(1R,2R)-1-[[[(S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoyl]amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro-1H-indole-2-carboxamide 597555-23-2P,


5-Chloro-N-[1-[(cyanomethyl)amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597555-25-4P, N-[(1R,2R)-1-[(2-Amino-2-oxoethyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro-1H-indole-2-carboxamide 597555-37-8P, N-[(1R,2R)-1-[(N-(2-Acetoxyacetyl)-N-

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)




RN 597555-25-4 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-[(2-Amino-2-oxoethyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597555-37-8 CAPLUS
 CN Glycine, N-[(acetyloxy)acetyl]-N-[(1R,2R)-2-[[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 597554-72-8P, 5-Chloro-2-[(N-(trans-1-hydroxyindan-2-yl)carbonyl)amino]indole 597554-75-1P, 5-Chloro-N-[(1R,2R)-1-

[(methylsulfonyl)amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597554-79-5P, N-[(1R*,2R*)-1-[(2-Carboxyacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloroindole-2-carboxamide 597554-83-1P, 5-Chloro-N-[(1R,2R)-1-[(3-methoxypropionyl)amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597554-87-5P, N-[(1R,2R)-1-[(Acetyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro-1H-indole-2-carboxamide 597554-93-3P, N-[(1R,2R)-1-[(2-Carbamoylacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloroindole-2-carboxamide 597554-95-5P, N-[(1R,2R)-1-[(2-Carboxyacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 chloroindole-2-carboxamide 597554-97-7P, 5-Chloro-N-[(1R,2R)-1-
 [(hydroxyacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide
 597554-98-8P, 5-Chloro-N-[(1R,2R)-1-[[3-hydroxy-2-
 (hydroxymethyl)propanoyl]amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-
 carboxamide 597555-00-5P, N-[(1R,2R)-1-[(3R)-3-Amino-3-
 carbamoylpropanoyl]amino]-2,3-dihydro-1H-inden-2-yl]-5-chloroindole-2-
 carboxamide 597555-01-6P, N-[(1R,2R)-1-[(3R)-3-Amino-3-
 carbamoylpropanoyl]amino]-2,3-dihydro-1H-inden-2-yl]-5-chloroindole-2-
 carboxamide trifluoroacetate 597555-02-7P 597555-03-8P


N-[(1R,2R)-1-[(Aminoacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro-1H-
 indole-2-carboxamide trifluoroacetate 597555-05-0P,
 5-Chloro-N-[(1S,2S)-1-[(methylsulfonyl)amino]-2,3-dihydro-1H-inden-2-yl]-
 1H-indole-2-carboxamide 597555-08-3P, 5-Chloro-N-[(1-
 [(hydroxyacetyl)amino]-2,3-dihydro-1H-inden-2-yl)-1H-indole-2-carboxamide
 597555-11-8P, 5-Chloro-N-[(1R,2R)-1-[[2-
 hydroxyethyl] (methyl)amino]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-1H-
 indole-2-carboxamide 597555-12-9P, 5-Chloro-N-[(1R,2R)-1-[[2-
 hydroxyethyl] (phenylmethyl)amino]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-
 1H-indole-2-carboxamide 597555-13-0P, 5-Chloro-N-[(1R,2R)-1-[[3-
 hydroxypiperidin-1-yl]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-
 carboxamide 597555-14-1P, 5-Chloro-N-[(1R,2R)-1-[[3-
 hydroxypyrrolidin-1-yl]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-
 2-carboxamide 597555-15-2P, N-[(1R,2R)-1-[[Bis(2-
 hydroxyethyl)amino]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro-1H-
 indole-2-carboxamide 597555-18-5P, N-[(1R,2R)-1-[(Aminoacetyl)amino]-2,3-
 dihydro-1H-inden-2-yl]-5-chloro-1H-indole-2-carboxamide 597555-22-1P,
 5-Chloro-N-[(1R,2R)-1-[[3-(3-Amino-3-carboxypropanoyl)amino]-2,3-
 dihydro-1H-inden-2-yl]-5-chloroindole-2-carboxamide 597555-20-9P,
 5-Chloro-N-[(1R,2R)-1-[[[chloromethyl]sulfonyl]amino]-2,3-dihydro-1H-
 inden-2-yl]-1H-indole-2-carboxamide 597555-22-1P,
 5-Chloro-N-[(1R,2R)-1-[[[trifluoromethyl]sulfonyl]amino]-2,3-dihydro-1H-
 inden-2-yl]-1H-indole-2-carboxamide 597555-24-3P, 5-Chloro-N-[(1R,2R)-1-
 [[(1H-tetrazol-5-yl)methyl]amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-
 carboxamide 597555-26-5P, N-[(1R,2R)-1-[(Carboxymethyl)amino]-
 2,3-dihydro-1H-inden-2-yl]-5-chloroindole-2-carboxamide
 597555-28-7P, N-[(1S,2S)-1-[Acetyl[(2-thienyl)methyl]amino]-2,3-
 dihydro-1H-inden-2-yl]-5-chloro-1H-indole-2-carboxamide
 597555-30-1P, N-[(1S,2S)-1-[N-Acetyl-N-(carboxymethyl)amino]-2,3-
 dihydro-1H-inden-2-yl]-5-chloroindole-2-carboxamide 597555-31-2P,
 N-[(1S,2S)-1-[N-Acetyl-N-[[2-(ethoxycarbonyl)cycloprop-1-
 yl]methyl]amino]-2,3-dihydro-1H-inden-2-yl]-5-chloroindole-2-carboxamide
 597555-32-3P, N-[(1R,2R)-1-[N-Acetyl-N-(carboxymethyl)amino]-2,3-
 dihydro-1H-inden-2-yl]-5-chloroindole-2-carboxamide 597555-34-5P,
 N-[(1R,2R)-1-[Bis(carboxymethyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-
 chloroindole-2-carboxamide 597555-35-6P, N-[(1R,2R)-1-
 [(Acetyl[(2-amino-2-oxoethyl)amino]-2,3-dihydro-1H-inden-2-yl)-5-chloro-1H-
 indole-2-carboxamide 597555-43-6P, 5-Chloro-N-[(1R,2R)-1-[(2R)-
 2,3-dihydroxypropyl]amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-
 carboxamide 597555-61-8P, 5-Chloro-2-(N-(1-hydroxyindan-2-
 yl)carbamoyl)indole

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 597554-83-1 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2-[[3-methoxy-1-
 oxopropyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597554-87-5 CAPLUS
 CN 1H-Indole-2-carboxamide,
 N-[(1R,2R)-1-(acetyl)amino]-2,3-dihydro-1H-inden-2-
 yl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597554-93-3 CAPLUS
 CN Propanediamide,
 N-[(1R,2R)-2-[[5-chloro-1H-indol-2-yl]carbonyl]amino]-2,3-
 dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RL: PAC (Pharmacological activity); SPH (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (drug candidate: prepn. of indolamide deriva. that possess glycogen
 phosphorylase inhibitory activity)
 RN 597554-72-8 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-hydroxy-1H-
 inden-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 597554-75-1 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-
 [(methylsulfonyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597554-79-5 CAPLUS
 CN Propanoic acid, 3-[[[(1R,2R)-2-[[5-chloro-1H-indol-2-yl]carbonyl]amino]-
 2,3-dihydro-1H-inden-1-yl]amino]-3-oxo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 597554-95-5 CAPLUS
 CN Propanoic acid, 3-[[[(1R,2R)-2-[[5-chloro-1H-indol-2-yl]carbonyl]amino]-
 2,3-dihydro-1H-inden-1-yl]amino]-3-oxo-, rel- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597554-97-7 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-
 [(hydroxyacetyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597554-98-8 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[[3-hydroxy-2-
 (hydroxymethyl)-1-oxopropyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 597555-00-5 CAPLUS
 CN Butanediamide, 2-amino-N4-[(1R,2R)-2-[[5-chloro-1H-indol-2-yl]carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-01-6 CAPLUS
 CN Butanediamide, 2-amino-N4-[(1R,2R)-2-[[5-chloro-1H-indol-2-yl]carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, (2R)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 597555-00-5
 CMF C22 H22 Cl N5 O3

Absolute stereochemistry.



L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 597555-05-0 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1S,2S)-2,3-dihydro-1-[(methylsulfonyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597555-08-3 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(hydroxyacetyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 597555-02-7 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-[(aminoacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-03-8 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-[(aminoacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro- (9CI) (CA INDEX NAME)


CM 1

CRN 597555-02-7
 CMF C20 H19 Cl N4 O2

Absolute stereochemistry.




L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 597555-11-8 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[[[2-(hydroxyethyl)methylamino]acetyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597555-12-9 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[[[2-(hydroxyethyl)(phenylmethyl)amino]acetyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597555-13-0 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[[[3-(hydroxy-1-piperidinyloxy)acetyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 597555-14-1 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(3-hydroxy-1-pyrrolidinyl)acetyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-15-2 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-[[bis(2-hydroxyethyl)amino]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 597555-22-1 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(2,3-dihydro-1-[[[(trifluoromethyl)sulfonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)




RN 597555-24-3 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(1H-tetrazol-5-ylmethyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597555-26-5 CAPLUS
 CN Glycine, N-[(1R,2R)-2-[[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-28-7 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1S,2S)-1-[acetyl(2-thienylmethyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 597555-18-5 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[[1-[(aminoacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro- (9CI) (CA INDEX NAME)




RN 597555-19-6 CAPLUS
 CN L-Asparagine, N-[2-[[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597555-20-9 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-1-[[[(chloromethyl)sulfonyl]amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 597555-30-1 CAPLUS
 CN Glycine, N-acetyl-N-[(1S,2S)-2-[[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597555-31-2 CAPLUS
 CN Cyclopropanecarboxylic acid, 2-[[[acetyl[(1S,2S)-2-[[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597555-32-3 CAPLUS
 CN Glycine, N-acetyl-N-[(1R,2R)-2-[[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 597555-34-5 CAPLUS
 CN Glycine, N-(carboxymethyl)-N-[(1R,2R)-2-[[5-chloro-1H-indol-2-yl]carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597555-35-6 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-[acetyl(2-amino-2-oxoethyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-43-6 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-1-[(2R)-2,3-dihydroxypropyl]amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 dihydro-1H-inden-2-yl]-5-chloro-1H-indole-2-carboxamide trifluoroacetate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of indolamide derivs. that possess glycogen phosphorylase
 inhibitory activity)


RN 597554-81-5 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl]-5-chloro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 597554-85-3 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-09-4 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-1-[(iodoacetyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)




RN 597555-10-7 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-1-[(chloroacetyl)amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 597555-61-8 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(2,3-dihydro-1H-inden-2-yl)-5-chloro-1H-indole-2-carboxamide (9CI) (CA INDEX NAME)



IT 597554-81-9P, N-(trans-1-Amino-2,3-dihydro-1H-inden-2-yl)-5-chloro-1H-indole-2-carboxamide 597554-85-3P, N-[(1R,2R)-1-Amino-2,3-dihydro-1H-inden-2-yl]-5-chloro-1H-indole-2-carboxamide 597555-09-4P, 5-Chloro-N-[(1-iodoacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597555-10-7P,


5-Chloro-N-[(1R,2R)-1-[(chloroacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597555-17-4P, N-[(1-Amino-2,3-dihydro-1H-inden-2-yl)-5-chloro-1H-indole-2-carboxamide trifluoroacetate 597555-21-0P, N-[(1R,2R)-1-Amino-2,3-dihydro-1H-inden-2-yl]-5-chloro-1H-indole-2-carboxamide trifluoroacetate 597555-27-6P, 1,1-Dimethylethyl

2-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]acetate 597555-29-8P, N-[(1S,2S)-1-Amino-2,3-dihydro-1H-inden-2-yl]-5-chloro-1H-indole-2-carboxamide 597555-33-4P, 1,1-Dimethylethyl 2-[acetyl[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]acetate 597555-39-0P, 1,1-Dimethylethyl

2-[(acetyloxy)acetyl][(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]acetate 597555-46-9P, 5-Chloro-2-[N-[(1-[(1,1-dimethylethoxy)carbonyl]amino]indan-2-yl)carbamoyl]indole 597555-50-5P, tert-Butyl

[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]carbamate 597555-53-6P, tert-Butyl [(1S,2S)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]carbamate 597555-59-4P 597556-42-8P, N-[(1S,2S)-1-Amino-2,3-

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 597555-17-4 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1-amino-2,3-dihydro-1H-inden-2-yl)-5-chloro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 597555-16-3

CMF C18 H16 Cl N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 597555-21-0 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl]-5-chloro-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 597554-85-3

CMF C18 H16 Cl N3 O

Absolute stereochemistry.

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 597555-27-6 CAPLUS
CN Glycine, N-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597555-29-8 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(1S,2S)-1-amino-2,3-dihydro-1H-inden-2-yl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 597555-50-5 CAPLUS
CN Carbamic acid, [(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597555-53-8 CAPLUS
CN Carbamic acid, [(1S,2S)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597555-59-4 CAPLUS
CN Glycine, N-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-N-(2-(1,1-dimethylethoxy)-2-oxoethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 597555-33-4 CAPLUS
CN Glycine, N-acetyl-N-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-39-0 CAPLUS
CN Glycine, N-[(acetyloxy)acetyl]-N-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597555-46-9 CAPLUS
CN Carbamic acid, [2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 597556-42-8 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(1S,2S)-1-amino-2,3-dihydro-1H-inden-2-yl]-5-chloro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 597555-29-8
CMF C18 H16 Cl N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT